Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Krishnathas 2017 Med Chem Comm

From Bioblast
Publications in the MiPMap
Krishnathas R, Bonke E, Dröse S, Zickermann V, Nasiri HR (2017) Identification of 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine as a novel, highly potent and specific inhibitor of mitochondrial complex I. Med Chem Comm 8:657-61.

» [1]

Krishnathas R, Bonke E, Droese S, Zickermann V, Nasiri HR (2017) Med Chem Comm

Abstract: By probing the quinone substrate binding site of mitochondrial complex I with a focused set of quinazoline-based compounds, we identified substitution patterns as being critical for the observed inhibition. The structure activity relationship study also resulted in the discovery of the quinazoline 4-N-[2-(4-phenoxyphenyl)ethyl]quinazoline-4,6-diamine (EVP4593) as a highly potent inhibitor of the multisubunitmembrane protein. EVP4593 specifically and effectively reduces the mitochondrial complex I-dependent respiration with no effect on the respiratory chain complexes II–IV. Similar to established Q-site inhibitors, EVP4593 elicits the release of reactive oxygen species at the flavin site of mitochondrial complex I. Recently, EVP4593 was nominated as a lead compound for the treatment of Huntingtons disease. Our results challenge the postulated primary mode-of-action of EVP4593 as an inhibitor of NF-κB pathway activation and/or store-operated calcium influx.

Bioblast editor: Kandolf G O2k-Network Lab: DE Frankfurt Droese S

Labels: MiParea: Respiration, Pharmacology;toxicology 

Organism: Rat  Tissue;cell: Heart  Preparation: Isolated mitochondria 

Regulation: Inhibitor  Coupling state: OXPHOS  Pathway: N, S  HRR: Oxygraph-2k